EVP of Glenmark Generics Inc., the subsidiary company of an Indian generic manufacturer, is considering his alternative on whether or not to proceed with Launch @ Risk in the U.S. marketplace. Defined as a "threat taken by a generic company when it places a product available on the market before concluding excellent patent litigations against it," Launch @ Risk is a widely acknowledged route to obtain an entry into the world's biggest and most lucrative pharmaceutical marketplace. Glenmark Generics has just got hold of permission from FDA to bring in market a cheaper generic version of the drug but the FDA permission has been challenged in the US Federal Court. While awaiting the court's opinion, the EVP must appraise his company’s choices and decide whether to carry on, in the interim, with the product launch.
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
PUBLICATION DATE: June 15, 2015 PRODUCT #: W15238-PDF-ENG
Related Case Solutions & Analyses:
Sun Hydraulics Corp. (A)
Oxipouco – An Endangered Species Resource Negotiation (A): SuperPharma – Confidential Instructions
Russell Mehta at Rosy Blue: A Diamantaire for Life!
Adapting to Climate Change: The Case of Suncor Energy and the Alberta Oil Sands
“Broadmoor Lives”: A New Orleans Neighborhood’s Battle To Recover from Hurricane Katrina (Sequel)
The Northwest Passage
K2: Brotherhood of the Rope (C)
Return Logic, Inc, (A)
Venture Capital Vignettes
Xyberspace Consulting, Inc.
